Market Analysis:
Gastro meetings
Theme: Novel Innovations In Gastroenterology
Meetings International will be holding its Global Experts Meeting entitled Focus on Gastroenterology from November 13-15, 2017. The theme of this year’s meeting is “Novel Innovations In Gastroenterology" which will provide an international platform for discussion of present and future challenges in Gastroenterology. World-leading practitioners, clinicians, educators and researchers will present cutting-edge and practical clinical techniques based upon widely accepted evidence and will introduce new and emerging research.
Importance & Scope:
Gastroenterology is the branch of medical sciences which deals with the path of logistic study, prevention and management of diseases related to liver, gall bladder, biliary tree and pancreas.
The global gastrointestinal market report offers the in-depth analysis of the revenue, market share, major market segments, different geographic regions, key players, premium trends and forecasts to 2022. It also focuses on the key drivers and also on opportunities in this market
Why Asia?
Gastroenterology in Asia will increase and expand its market share. The drivers behind the expansion are two-fold: first the expansion of local companies in Asia and secondly, Western pharma outsourcing its research and manufacturing operations to Asia, particularly China and India.
Conference Highlights:
· Gastrointestinal Advanced Treatment Procedure
· New Biology of Gastrointestinal Hormones
· Digestive Diseases
· Advances in Liver Diseases
· Future of Endoscopy in Gastroenterology
· Gastroesophageal Reflux Disease (GERD)
· Gastrointestinal Oncology
· Pancreatic Disease
· Liver Fibrosis
· Inflammatory Bowel Disease
· Neuro Gastroenterology
· Probiotics in Gastrointestinal Disorders
Why to attend???
Gastroenterology Meeting 2017 provides a valuable opportunity to stay up-to-date and ahead on the legislation and latest innovations. Unrivalled opportunity to do business and network with thousands of senior decision makers looking to discover the latest benefits and solutions to engage their staff. Conduct meetings with current and potential scientists, distribute information, presentations, make a splash with new developments, and receive name recognition at this 3-day event. World-renowned speakers, developments, the most recent techniques, and the newest updates in separation techniques are hallmarks of this conference.
A Unique Opportunity for Advertisers and Sponsors at this International event:
Major Worldwide Gastroenterology Organizations:
Emirats gastroenterology and Hepatology Society(EGHS)
European association for the study of the liver
The International association for the study of the liver
The Saudi society of Peadiatric Gastroenterology, Hepatology and Nutrition(saspghan)
The Pan Arab society of Pediatric Gastroenterology, Hepatology and Nutrition (PASPGHAN))
The Japan Society of Hepatology
The Egyptian Society of Hepatology, Gastroenterology and Infectious Diseases in Alexandria (ESHGID)
The Egyptian Hepato-Pancreato-Biliary Society
Hepatology Society of the Philippines
Gastroenterology Associated Universities
In Melbourne:
University of Melbourne |
||
Central Melbourne Gastroenterology |
||
Melbourne GI and Endoscopy |
||
Melbourne Gastrointestinal Group |
||
Monash University Clayton Campus |
||
The Royal Melbourne Hospital |
||
Gow Paul |
||
Companies Associated with Gastroenterology
3M Pharmaceuticals Pty Ltd |
||
Abbott Australasia Pty Ltd |
||
Alcon Laboratories Pty Ltd |
||
Allergan Australia Pty Ltd |
||
Alphapharm Pty. Ltd |
||
Altana Pharma Pty. Ltd. |
||
Amersham Health Pty Limited |
||
Amgen Australia Pty Ltd |
||
AstraZeneca Pty Ltd |
||
Aurora BioScience Pty. Ltd. |
||
Australian Radioisotopes |
||
AVENTIS PASTEUR Pty Ltd |
||
AZA Research Pty Ltd |
||
Bausch & Lomb Australia Pty. Ltd. |
||
Baxter Healthcare Pty. Ltd. |
||
Bayer Australia Ltd |
||
BD (Becton Dickinson) |
||
Biochemie Australia Pty Ltd |
||
Biochemie Australia Pty Ltd |
||
Biogen Australia Pty Ltd |
||
Boehringer Ingelheim Pty Ltd |
||
Boots Healthcare Australia Pty Ltd |
||
Boron Molecular Limited |
||
Boucher & Muir Pty Ltd |
||
Bristol-Myers Squibb Australia Pty Ltd |
||
CSL Limited |
||
Douglas Pharmaceuticals |
||
Eli Lilly Australia Pty Ltd |
||
Faulding Pharmaceuticals |
||
GlaxoSmithKline Australia |
||
Hamilton Pharmaceuticals Pty Ltd |
||
Hoechst Marion Roussel Australia Pty Ltd |
||
Leo Pharmaceutical Products Ltd |
||
Leo Pharmaceutical Products Ltd |
||
Novo Nordisk Pharmaceuticals Pty Ltd |
||
Otsuka Pharmaceutical Australia Pty Ltd |
||
Pfizer Pty Ltd |
Evolution of HCV Therapy:
In the United States, 20 percent to 30 percent of people living with HIV are coinfected with HCV. Hepatitis C is common among people living with HIV. This means that about 225,000 to 330,000 people in the United States are living with both viruses. The majority of people living with hepatitis C do not know they have it. The most common route of transmission in the UK is using non-sterile needles and other equipment for injecting drugs. 90 percent of people who got HIV from injecting drugs are also infected with HCV. This is because both viruses can be spread easily through blood and blood products.
Active Member of IRAQI MEDICAL SCIENCES ASSOCIATION, USA (IMSA-USA)
Iraq